Lingyan Jian

Lingyan Jian

Auto-generated profile, based on publicly available information

Lingyan Jian

Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2022 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
RBRuixue Bai
Ruixue Bai
YLYunong Li
Yunong Li
LJLingyan Jian
Lingyan Jian
YYYuehui Yang
Yuehui Yang
LZLin Zhao
Lin Zhao
MWMinjie Wei
Minjie Wei
Given that hypoxia is a persistent physiological feature of many different solid tumors and a key driver for cancer malignancy, it is thought to be a major target in cancer treatment recently. Tumor-associated macrophages (TAMs) are the most abundant immune cells in the tumor microenvironment (TME), which have a large impact on tumor development and immunotherapy. TAMs massively accumulate within hypoxic tumor regions. TAMs and hypoxia represent a deadly combination because hypoxia has been suggested to induce a pro-tumorigenic macrophage phenotype. Hypoxia not only directly affects macrophage polarization, but it also has an indirect effect by altering the communication between tumor cells and macrophages. For example, hypoxia can influence the expression of chemokines and exosomes, both of which have profound impacts on the recipient cells. Recently, it has been demonstrated that the intricate interaction between cancer cells and TAMs in the hypoxic TME is relevant to poor prognosis and increased tumor malignancy. However, there are no comprehensive literature reviews on the molecular mechanisms underlying the hypoxia-mediated communication between tumor cells and TAMs. Therefore, this review has the aim to collect all recently available data on this topic and provide insights for developing novel therapeutic strategies for reducing the effects of hypoxia.

5 August 2020 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
LZLei Zhao
Lei Zhao
SWShiqi Wang
Shiqi Wang
XLXiaobing Li
Xiaobing Li
XHXiaojing He
Xiaojing He
LJLingyan Jian
Lingyan Jian
Fluoroquinolone resistance in Pseudomonas aeruginosa typically arises through site-specific mutations and overexpression of efflux pumps. In this study, we investigated the dynamics of different resistance mechanisms in P. aeruginosa populations that have evolved under fluoroquinolone pressure, as well as the interactions between these mechanisms in evolutionary trajectories. Bacteria of strain ATCC27853 were selected under different concentrations of ciprofloxacin and levofloxacin for six parallel lineages, followed by amplification of four target genes in the quinolone-resistance determining region (QRDR) and Sanger sequencing to identify the mutations. The expression of four efflux pump proteins was evaluated by real-time polymerase chain reaction using the relative quantitation method, with the ATCC27853 strain used as a control. We found that ciprofloxacin killed P. aeruginosa sooner than did levofloxacin. Further, we identified five different mutations in three subunits of QRDRs, with gyrA as the main mutated gene associated with conferring fluoroquinolone resistance. Additionally, we found a larger number of mutations appearing at 2 mg/L and 4 mg/L of ciprofloxacin and levofloxacin, respectively. Moreover, we identified the main efflux pump being expressed as MexCD-OprJ, with initial overexpression observed at 0.25 mg/L and 0.5 mg/L of ciprofloxacin and levofloxacin, respectively. These results demonstrated gyrA83 mutation and MexCD-OprJ overexpression as the primary mechanism conferring ciprofloxacin and levofloxacin resistance in P. aeruginosa. In addition, we also show that ciprofloxacin exhibited a stronger ability to kill the bacteria while potentially rendering it more susceptible to resistance.

1 May 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TRTianyang Ren
Tianyang Ren
XZXuehua Zheng
Xuehua Zheng
RBRuixue Bai
Ruixue Bai
YYYuehui Yang
Yuehui Yang
LJLingyan Jian
Lingyan Jian

1 February 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
XLXin-Yang Li
Xin-Yang Li
DWDe-Pu Wang
De-Pu Wang
SLShuai Li
Shuai Li
WXWen-Han Xue
Wen-Han Xue
XQXin-Hua Qian
Xin-Hua Qian
LJLing-Yan Jian
Ling-Yan Jian

20 February 2021 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
XFXin‐Yu Fan
Xin‐Yu Fan
GSGuang Shi
Guang Shi
XHXiao‐Jing He
Xiao‐Jing He
XLXin‐Yang Li
Xin‐Yang Li
YWYu‐Xiao Wan
Yu‐Xiao Wan
LJLing‐Yan Jian
Ling‐Yan Jian

1 January 2022 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TRTianyang Ren
Tianyang Ren
XZXuehua Zheng
Xuehua Zheng
RBRuixue Bai
Ruixue Bai
YYYuehui Yang
Yuehui Yang
LJLingyan Jian
Lingyan Jian